Ph I Dose Escalation Trial of Vandetanib in Combo w Etoposide for Malignant Gliomas

PHASE1CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

October 31, 2010

Study Completion Date

May 31, 2011

Conditions
GliosarcomaGlioblastoma
Interventions
DRUG

Vandetanib and Etoposide

Vandetanib will be given orally once day. Swallow tablet with 240 ml of non-carbonated water. Initial dose is 100 mg/day for stratum 1 \& 200 mg/day for stratum 2. Etoposide will be taken by mouth in capsule form at a flat dose of 50 mg/day for 1st 21 days of 28-day cycle. You will not take etoposide for following 7 days of the cycle.

Trial Locations (1)

27710

Duke University Health System, Durham

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Annick Desjardins

OTHER